Literature DB >> 14575897

Interrelationships between mu opioid and melanocortin receptors in mediating food intake in rats.

Henya C Grossman1, Maria M Hadjimarkou, Robert M Silva, Silvia Q Giraudo, Richard J Bodnar.   

Abstract

The present study examined the interrelationships between feeding responses produced by mu opioid receptor agonists and melanocortin-3 or 4 (MC-3/4) receptor antagonists. Feeding induced by the mu-sensitive opioid peptide, beta-endorphin (betaEND, 10 microg, i.c.v.) was significantly and dose-dependently reduced by pretreatment with the MC-3/4 receptor agonist, melanotan-II (MTII: 0.01-10 nmol, i.c.v.). Moreover, the selective mu opioid antagonist, beta-funaltrexamine (betaFNA: 2-20 mug, i.c.v.), significantly and dose-dependently reduced feeding and weight gain elicited by the potent MC-3/4 receptor antagonist, SHU-9119 (0.5 nmol, i.c.v.), especially at those intake periods (24-48 h) when SHU-9119 produced maximal ingestive effects. These data extend previous findings demonstrating interactions between opioid and melanocortin receptors in the mediation of food intake.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575897     DOI: 10.1016/s0006-8993(03)03442-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  β-Endorphin antagonizes the effects of α-MSH on food intake and body weight.

Authors:  Roxanne Dutia; Kana Meece; Shveta Dighe; Andrea J Kim; Sharon L Wardlaw
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

2.  HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice.

Authors:  N Eser Ercil; Ruggero Galici; Robert A Kesterson
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

Review 3.  Hypothalamic proopiomelanocortin processing and the regulation of energy balance.

Authors:  Sharon L Wardlaw
Journal:  Eur J Pharmacol       Date:  2011-01-03       Impact factor: 4.432

4.  MC4-R signaling within the nucleus accumbens shell, but not the lateral hypothalamus, modulates ethanol palatability in rats.

Authors:  Jose M Lerma-Cabrera; Francisca Carvajal; Gabriela Chotro; Mirari Gaztañaga; Montserrat Navarro; Todd E Thiele; Inmaculada Cubero
Journal:  Behav Brain Res       Date:  2012-11-09       Impact factor: 3.332

Review 5.  Pharmacological Effects and Regulatory Mechanisms of Tobacco Smoking Effects on Food Intake and Weight Control.

Authors:  Tongyuan Hu; Zhongli Yang; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2018-07-27       Impact factor: 4.147

6.  Differentiation of hypothalamic-like neurons from human pluripotent stem cells.

Authors:  Liheng Wang; Kana Meece; Damian J Williams; Kinyui Alice Lo; Matthew Zimmer; Garrett Heinrich; Jayne Martin Carli; Charles A Leduc; Lei Sun; Lori M Zeltser; Matthew Freeby; Robin Goland; Stephen H Tsang; Sharon L Wardlaw; Dieter Egli; Rudolph L Leibel
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

7.  Amygdalar opioids modulate hypothalamic melanocortin-induced anorexia.

Authors:  Tiffany R Beckman; Qiuying Shi; Allen S Levine; Charles J Billington
Journal:  Physiol Behav       Date:  2008-12-24

8.  Pharmacotherapies for obesity: past, current, and future therapies.

Authors:  Lisa L Ioannides-Demos; Loretta Piccenna; John J McNeil
Journal:  J Obes       Date:  2010-12-12

9.  Nucleus Accumbens MC4-R Stimulation Reduces Food and Ethanol Intake in Adult Rats Regardless of Binge-Like Ethanol Exposure during Adolescence.

Authors:  Francisca Carvajal; José M Lerma-Cabrera; Manuel Alcaraz-Iborra; Montserrat Navarro; Todd E Thiele; Inmaculada Cubero
Journal:  Front Behav Neurosci       Date:  2017-09-07       Impact factor: 3.558

10.  Effects of Opioid Antagonism on Cerebrospinal Fluid Melanocortin Peptides and Cortisol Levels in Humans.

Authors:  Rebecca J Gordon; Sunil K Panigrahi; Kana Meece; Deniz Atalayer; Richard Smiley; Sharon L Wardlaw
Journal:  J Endocr Soc       Date:  2017-08-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.